Stifel analyst Annabel Samimy reiterated a Buy rating and $35 price target on Valeant Pharmaceuticals (NYSE: VRX) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE